GenomOncology today announced a collaboration with Roswell Park Cancer Institute (RPCI) to develop an informatics solution that enables the association of Next Generation Sequencing results with knowledge resources to define actionable mutations.
"The challenges of translating the vast amounts of data from next-generation sequencing into a resource that can be easily and effectively incorporated into clinical and research programs are significant," said Dr. Carl Morrison, Executive Director of the Center for Personalized Medicine at Roswell Park. "We need next-generation tools that will help us to deliver the best and most appropriate therapies to our patients through a streamlined process."
GenomOncology and RPCI are working together to develop a software platform that integrates laboratory information management systems, electronic health records, information technology and bioinformatics and that provides a workflow enabling genomic analysts and pathologists to create actionable reports.
GenomOncology will be demonstrating this software platform at two upcoming conferences, Advances in Genome Biology & Technology (AGBT) in February and United States & Canadian Academy of Pathology (USCAP) in March.
New research unveils mechanism behind deadly neuroendocrine prostate cancer